Alzheimer’s Disease: Tau Protein Predicts Early Memory Loss
Posted on by Dr. Francis Collins
In people with Alzheimer’s disease, changes in the brain begin many years before the first sign of memory problems. Those changes include the gradual accumulation of beta-amyloid peptides and tau proteins, which form plaques and tangles that are considered hallmarks of the disease. While amyloid plaques have received much attention as an early indicator of disease, until very recently there hadn’t been any way during life to measure the buildup of tau protein in the brain. As a result, much less is known about the timing and distribution of tau tangles and its relationship to memory loss.
Now, in a study published in Science Translational Medicine, an NIH-supported research team has produced some of the first maps showing where tau proteins build up in the brains of people with early Alzheimer’s disease . The new findings suggest that while beta-amyloid remains a reliable early sign of Alzheimer’s disease, tau may be a more informative predictor of a person’s cognitive decline and potential response to treatment.
The study, led by Beau Ances and Matthew Brier of Washington University, St. Louis, set out to explore how the accumulation of tau and beta-amyloid, though linked to different pathological processes, are related clinically in tracking the progression of Alzheimer’s disease. To take a look, they imaged beta-amyloid and used a newly available imaging agent for tau that, when injected into a person’s bloodstream, binds to the protein and makes it visible in positron imaging tomography (PET) scans of the brain.
The researchers studied 46 people—36 healthy controls and 10 people diagnosed with mild Alzheimer’s disease. The participants, who averaged 75 years old, underwent an MRI and two PET scans to visualize the distribution of both tau and beta-amyloid across the brain. All participants also completed standard memory tests for dementia. In addition, most study participants had their tau and beta-amyloid levels measured in cerebrospinal fluid and underwent neuropsychological testing.
The brain scans revealed markedly increased tau levels in the brains of people with early Alzheimer’s disease compared to healthy participants. Those differences were particularly notable in the temporal lobe, a portion of the brain known to play a role in memory, and in the cerebral cortex. The researchers also observed increases in beta-amyloid in people with Alzheimer’s disease as well as in some of the cognitively normal study participants. Those amyloid plaques tended to build up most prominently in the brain’s frontal and parietal lobes, key areas involved in integrating sensory information and higher cognitive processes, including memory and executive function.
Although beta-amyloid and tau tend to concentrate in different parts of the brain, the researchers found that tau accumulation in the temporal lobe tracked closely with symptoms of memory loss, as measured on standard pencil and paper tests of cognitive ability. The beta-amyloid scans, however, didn’t show the same ability to predict a person’s cognitive performance.
While measures of overall tau burden based on the PET scans closely mirrored those obtained from analyses of cerebrospinal fluid, the images offer much more information about where tau tends to accumulate as a person’s memory begins to worsen. While additional research is needed in more people over time, Ances and his colleagues now suspect that beta-amyloid accumulates diffusely throughout the brain first. Their data also suggest memory troubles surface only later, once the presence of both amyloid and tau deposits within certain brain regions cause a person to show symptoms of the disease.
Amyloid imaging has great promise for use in the early diagnosis of Alzheimer’s disease. But, in many cases, people don’t see their doctor with concerns about Alzheimer’s until memory problems have already begun, and it appears that tau might provide a useful tool for staging their disease. As progress is made in the development of new Alzheimer’s treatments, including those that target tau and beta-amyloid, PET scans might prove useful for doctors in choosing the therapy most likely to help a patient and monitor its effects on disease progression.
Meanwhile, NIH-supported research is specifically funding PET scans of tau in clinical trials. A prime example is the Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD) Biomarkers Project, overseen by NIH’s National Institute on Aging. This consortium of three clinical trials, which is testing anti-amyloid therapies to help prevent or delay Alzheimer’s disease, has already incorporated tau imaging.
This progress in imaging tau and predicting cognitive decline may be helpful for the approximately 5 million Americans already affected by Alzheimer’s disease [2,3]. But more than that, this advance will provide researchers with a critical tool to test an array of new preventive therapies, the development of which is an extremely high priority.
 Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease. Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, Benzinger TL, Ances BM. Sci Transl Med. 2016 May 11;8(338):338ra66.
 Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Hebert LE, Weuve J, Scherr PA, Evans DL.Neurology. 2013 May 7;80:1778-1783.
 Alzheimer’s Disease. Centers for Disease Control and Prevention. 2016 March 5.
Alzheimer’s Disease Fact Sheet (National Institute on Aging/NIH)
Beau Ances (Washington University School of Medicine, St. Louis)
Accelerating Medicines Partnership (NIH)
NIH Support: National Institute on Aging; National Institute of Neurological Disorders and Stroke; National Center for Advancing Translational Sciences
- Click to share on LinkedIn (Opens in new window)
- Click to share on Pinterest (Opens in new window)
- Click to share on Tumblr (Opens in new window)
- Click to share on Reddit (Opens in new window)
- Click to share on Telegram (Opens in new window)
- Click to share on WhatsApp (Opens in new window)
- Click to share on Skype (Opens in new window)
- Click to print (Opens in new window)
Tags: Accelerating Medicines Partnership, age-related memory loss, aging, Alzheimer’s disease, AMP, AMP-AD, ß-amyloid, beta amyloid, brain, brain scan, cerebral cortex, cognitive decline, dementia, early Alzheimer's disease, frontal lobe, imaging, memory, memory loss, neurological disease, neurology, parietal lobe, PET scans, tau, tau protein, temporal lobe, translational medicine
I hope everyone will read Woodrow Monte’s wonderful book on methanol toxicity, While Science Sleeps. He makes an overwhelming case that this is the root cause of dementia and athersoclerosis.
This was nice information. Thanks for good writing and sharing
Amyloid peptides and tau tangles are the consequence of two interrelated processes involving the release of intracellular calcium and peroxynitrite. The same type of receptors (g protein-coupled receptors, receptor tyrosine kinase receptors, ionotropic receptors, and metabotropic receptors) and enzyme (phospholipase C) trigger both. The release of intracellular calcium, though involves the agonism of inositol triphosphate receptors whereas peroxynitrite formation is via activation of protein kinase C and NMDA receptors.
The amyloid precursor protein and amyloid oligomers increase protein kinase C activity via g protein-coupled receptors. However, it was recently found that without the activation of protein kinase C, amyloid oligomers do not damage the brain. Without activation of protein kinase C there is no peroxynitrite and without peroxynitrite there is no Alzheimer’s disease.
Peroxynitrite mediates the nitration and hyperphosphorylation of tau proteins interfering with neurotransmissions, inhibits the release and synthesis of neurotransmitters involved in short-term memory, mood, sleep, social recognition, and alertness, inhibits the transport of glucose and reduces levels of oxygen in the brain which can cause delusions, can elicit hallucinations, anxiety, and aggression, prevents the regeneration of neurons in the hippocampus, and leads to the death of neurons via activation of caspase 3.
Peroxynitrite scavengers have partially reversed Alzheimer’s disease in several small-scale clinical trials. This includes aromatherapy with rosemary, lemon, orange, and lavender essential oils (Jimbo 2009), Korean red ginseng (Heo 2011), and heat processed ginseng (Heo 2012). CBD oil from marijuana has also shown promising results in mice studies and in human case studies.
As long as researchers continue to insist that amyloid peptide and misfolded tau proteins are the cause of Alzheimer’s disease and as long as funds go almost solely to drug-based “solutions” for the disease, Alzheimer’s disease will remain unchecked for decades. Once the paradigm has shifted, effective treatments for Alzheimer’s disease can be developed in just a few years.
This study seems a bit weak. What can you really garner from 10 patients who have a tenuous diagnosis of “mild Alzheimer’s”? Exactly what is “mild Alzheimer’s”. I have found that you can’t judge much from paper tests. In order to validate the 10 test subjects, you would have to first rule out all other causes of the subjects’ memory impairment. That there are over 70 potential causes for dementia is problematic to any current research.
This study and others fail to consider that tau and amyloid may be the result of some other problem rather than a cause. It seems probable that the brain and body is trying to repair some other issue – perhaps micro-infarcts or chemical imbalances or depletion of some resources that the brain needs.
It is even possible that a reduced blood flow to the brain could result in the body trying to restore proper oxygenation to neurons. Who knows?
I just think that addressing the tau/amyloid component may be missing the point. It could be like preventing the formation of scabs on a cut. I’m not so confident that plaques and tangles are a disease problem versus the bodies own attempt to repair some other problem.
My grandma got Alzheimer’s a couple years ago. I wonder if people have made cures for it. It was so sad, because it happened slowly. She just slowly started forgetting different things. I remember when I was younger and she would always make the best bread. I loved to help her make the dough, it was fun.
Thank you for sharing this new information. We deal with the families of seniors with Alzheimer’s every day. It’s such a hard disease and we follow it closely so we can better help our loved ones.